ПОЛИМОРФИЗМ ГЕНА ИНГИБИТОРА АКТИВАТОРА ПЛАЗМИНОГЕНА В ОЦЕНКЕ РИСКА РАЗВИТИЯ ТРОМБОЗОВ РАЗЛИЧНОЙ ЛОКАЛИЗАЦИИ (ПИЛОТНОЕ ИССЛЕДОВАНИЕ)

Aim. Assessment of the impact of genetic polymorphism of rs1799889 gene of PAI-1 inhypofibrinolytic state development, with the inclusion of the protein product amount shifts, in patients with thrombosis of different localizations. Material and methods. Totally 50 patients studied with thrombosis of different localization and etiology in anamnesis, and 25 controls — almost healthy donors, living on theterritoryofNovosibirskcity and the region. All patients underwent genotyping of polymorphism -675 4G/5G of the PAI-1 gene, and concentration of plasminogen activator inhibitor (PAI1) in blood plasma measurement. Results. In the groups of patients the prevalence studied of the gene PAI-1 variants -675 4G/5G, and the level of PAI1 measured, the influence of genotypes on the level of protein assessed. Assessment of allele variant 4G and high level of PAI1 is highly informative for the estimation of thrombosis risk. Conclusion. Genotypes 4G/4G and 5G/4G of gene PAI1, together with increased level of PAI1 are diagnostically important markers of endothelium dysfunction, hypo fibrinolysis condition and hence are predictors of clotting.